BENGALURU / NEW DELHI — An Indian multicentre phase III trial found that an olanzapine-based regimen, which is non-steroidal, was not inferior to the standard dexamethasone-based prophylaxis, which is a steroid, for vomiting control. More research, however, is needed to establish the findings widely. The development, reported on November 1, 2026, has drawn close scrutiny from domain specialists and policy observers examining its wider operational and institutional impact.
Industry executives and digital policy researchers noted that the rapid evolution of enterprise compute infrastructure, artificial intelligence deployment, and cybersecurity compliance standards is reshaping operational priorities across India’s technology corridor.
Regulatory frameworks governing data protection, platform accountability, and sovereign cloud capacity continue to draw sustained engagement from both global technology firms and domestic startups.
